From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future
From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future This article traces the evolution of API-in-capsule (AIC)...
Dr. Dave Seaward : 20 January 2022
PDF File: Cell and Gene Therapy: Converting a Rolls-Royce into a Ford?
With promising applications in the personalised medicines field, Cell and Gene Therapies are becoming more and more relevant. This, alongside 3Ps experience in the manufacturing of said therapies, has inspired 3P Founder and Projects Director Dave Seaward, to write a new blog series all about ATMPs!
Click the pdf link above and take a read of the first blog in the series.
This first blog focuses around the manufacture of cell and gene therapies with an interesting analogy to the automotive industry. It also looks at how 3P innovation can help with the manufacture of these life-changing ATMPs.
From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future This article traces the evolution of API-in-capsule (AIC)...
The revision of EU GMP Annex 1 has redefined expectations for sterile manufacturing across the life sciences sector and nowhere is this felt more...
Today’s pharmaceutical landscape positions 'sustainability' as an operational imperative. Manufacturers face increasing regulatory, societal, and...